DaVita Labs and Myriad RBM announce biomarker research collaboration
7 July 2014 | By Myriad RBM
Collaboration will focus on development of novel diagnostic tests for dialysis patients...
List view / Grid view
News
Drug Discovery Conversations: Brian Pollok, Entrepreneur-in-Residence, University of Virginia
7 July 2014 | By Oxford Global
Oxford Global Q&A Session with Brian Pollok, Entrepreneur-In-Residence, University of Virginia...
MRC Technology and AstraZeneca renew collaboration to identify novel targets for discovery research
3 July 2014 | By MRC Technology
Initiative brings together global expertise to share compound libraries and streamline drug discovery...
Actavis completes acquisition of Furiex Pharmaceuticals
3 July 2014 | By Actavis
Actavis plc announced that its subsidiary Forest Laboratories, LLC has successfully completed its acquisition of Furiex Pharmaceuticals, Inc...
Roche announces definitive agreement to acquire Seragon Pharmaceuticals
2 July 2014 | By Roche
Roche announced that Genentech has entered into a definitive agreement to acquire Seragon Pharmaceuticals, Inc. (Seragon), a privately held biotechnology company based in San Diego, California, USA...
Taiho Oncology, Inc. announces results from TAS-102 global Phase III RECOURSE trial in refractory metastatic colorectal cancer
30 June 2014 | By Taiho Oncology
Taiho Oncology, Inc. announced detailed findings from its global Phase III RECOURSE trial of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug...
Mundipharma EDO GmbH shows strong activity in early development in oncology
27 June 2014 | By Mundipharma
Mundipharma’s network of independent associated companies has been extended to form a new company called Mundipharma EDO GmbH with the purpose of building a robust and sustainable pipeline in oncology...
AbbVie announces initiation of pivotal Phase III study of Veliparib (ABT-888) in patients with advanced breast cancer
26 June 2014 | By AbbVie
AbbVie announced the initiation of a Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888)...
GSK announces the start of a phase III study with eltrombopag in patients with myelodysplastic syndromes
26 June 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced the start of a Phase III study, SUPPORT (TRC112121), to evaluate the platelet supportive care effects of eltrombopag (Promacta™/Revolade™)...
Phase 3 first-line melanoma study of Nivolumab, an investigational PD-1 checkpoint inhibitor, demonstrates superior overall survival compared to Dacarbazine; study stopped early
25 June 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced that a randomized blinded comparative Phase 3 study evaluating nivolumab versus dacarbazine in patients with previously untreated BRAF wild-type advanced melanoma...
Myriad announces diabetes collaboration with Sanofi
24 June 2014 | By Myriad RBM
Myriad Genetics announced that Myriad RBM has entered into a research collaboration with Sanofi...
Abbott to acquire Veropharm
24 June 2014 | By Abbott
Abbott announced a definitive agreement to acquire Veropharm, a leading Russian pharmaceutical manufacturer...
Phase 3a liraglutide 3 mg trial demonstrated significant weight loss and improved cardiovascular risk factors in adults with obesity and type 2 diabetes compared with placebo
23 June 2014 | By Novo Nordisk
New data from the phase 3a SCALE™ Diabetes trial were presented at the International Congress of Endocrinology and the Endocrine Society’s meeting, investigating the effect of liraglutide 3 mg in adults...
MSD begins tender offer to acquire Idenix
23 June 2014 | By Merck
MSD is commencing, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Idenix Pharmaceuticals, Inc...
Sanofi reports positive Phase 3 results for Toujeo®
19 June 2014 | By Sanofi
Sanofi announced that, in a pooled analysis, investigational therapy Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) consistently showed significantly fewer low blood sugar events (hypoglycemia)...